The loss of vital cells within healthy tissues contributes to the development, progression and
treatment outcomes of many human disorders, including neurological and infectious …

BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

Background Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive
hematologic cancer that is caused by transformed plasmacytoid dendritic cells that …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized
by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other …

Introduction Venetoclax (VEN), a selective BCL2 inhibitor, has single‐agent activity in
relapsed and refractory (R/R) acute myeloid leukemia (AML), and efficacy in lower intensity …

Defects in apoptotic cell death can promote cancer and impair responses of malignant cells
to anti-cancer therapy. Pro-survival BCL-2 proteins prevent apoptosis by keeping the cell …

Intrinsic apoptosis is controlled by the BCL-2 family of proteins but the complexity of intra-
family interactions makes it challenging to predict cell fate via standard molecular biology …

Abstract B-cell lymphoma 2 (BCL2) is a key protein regulator of apoptosis. It is variably
highly expressed in many hematological malignancies, providing protection from cell death …

Disruption of the physiologic balance between cell proliferation and cell death is an
important step of cancer development. Increased resistance to apoptosis is a key oncogenic …

Acquired resistance to BH3 mimetic antagonists of BCL-2 and MCL-1 is an important clinical
problem. Using acute myelogenous leukemia (AML) patient-derived xenograft (PDX) models …